[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"soft-tissue-sarcoma-adult\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:soft-tissue-sarcoma-adult":307},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,50,82,115,147,169,197,234,260,287],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100631983","phase-2-assessment-of-the-long-term-efficacy-of-moderately-hypofractionated-neoadjuvant-radiotherapy-soft-tissue-sarcoma-in-the-limbs-or-trunk-wall-100631983",false,"NCT07507773","Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall","Phase II Clinical Trial Assessing the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall, Incorporating Translationnal Research","NEORASARC","Inclusion Criteria:\n\n* Patient aged ≥ 18 years ;\n* Localised sarcoma of a limb, the root of a limb, or the trunk wall ;\n* Histologically confirmed diagnosis of soft tissue sarcoma regardless of the grade ;\n* Diagnosis biopsy performed at Centre Oscar Lambret, with specimen available for translational research ;\n* Indication of neoadjuvant radiotherapy according to the multidisciplinary consultation meeting ;\n* Tumor considered operable with a curative intent and conservative intent according to the multidisciplinary consultation meeting ;\n* Affiliation to the French National Social Security System ;\n* Informed and signed consent\n\nExclusion Criteria:\n\n* Metastatic disease (including local lymph node diffusion) ;\n* Visceral or retroperitoneal sarcoma ;\n* Tumor considered inoperable even after radiotherapy, according to the multidisciplinary consultation meeting ;\n* Indication of neoadjuvant or adjuvant chemotherapy ;\n* Ewing tumor of soft tissue, desmoid tumor, embryonal or alveolar rhabdomyosarcoma ;\n* Pregnant or breastfeeding women ;\n* Patients under protective measures ;\n* Patient refusal.","ALL","18 Years",{"count":20,"type":21},135,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This trial aims to assess the long-term efficacy of moderately hypofractionated neoadjuvant radiotherapy for soft tissue sarcoma in the limbs or trunk wall. The primary outcome is local disease control, assessed by the cumulative incidence of progression\u002Frecurrence.\n\nAfter informed consent has been obtained and eligibility criteria have been checked, a baseline assessment will be performed followed by the experimental treatment: intensity-modulated radiotherapy with a moderately hypofractionated regimen consisting in 15 fractions of 2.7 Gy administered over 3 weeks.\n\na follow-up assessment will be performed 3 to 4 weeks after the last radiotherapy session.\n\nTumor resection will be performed 4 to 8 weeks after the radiotherapy. Patients will then be followed up until the end of the study; planned 5 years after the last inclusion.\n\nRadiotherapy will be evaluated in terms of safety and efficacy.",[27,28,29,30],"Soft Tissue Sarcoma Adult","Soft Tissue Sarcoma (Excluding GIST)","Soft Tissue Sarcoma of the Trunk and Extremities","Soft Tissue Sarcoma of the Limb",[32,33,34,35,36],"Sarcoma","Trunk","Limb","Radiotherapy","Neoadjuvant","RECRUITING","2026-06-18",{"date":40,"type":41},"2026-06-22","ACTUAL",{"date":43,"type":21},"2026-06-01",{"date":45,"type":21},"2035-06-01",{"name":47,"class":48},"Centre Oscar Lambret","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":49},"100406791","phase-1-retifanlimab-anti-pd-1-antibody-with-gemcitabine-and-docetaxel-in-patients-with-advanced-soft-tissue-sarcoma-100406791","NCT04577014","Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma","A Multi-cohort Study of Retifanlimab With or Without Gemcitabine and Docetaxel in Patients With Advanced Sarcoma","Inclusion Criteria:\n\n* Diagnosis of metastatic or locally advanced and unresectable high-grade soft tissue sarcoma. Unresectable is defined as:\n\n  1. primary tumor cannot be safely removed surgically, or\n  2. primary tumor would benefit from systemic therapy prior to a surgical approach\n* Be willing and able to provide written informed consent\n* Must consent to mandatory tumor biopsy (if deemed safe and feasible) for research studies at screening, if archival tissue is not available, and at C1D15, C3D15.\n* Age ≥ 18 years\n* ECOG performance status ≤ 1\n* Presence of measurable disease per RECIST v1.1\n\n  * Target lesions must not be chosen from a previously irradiated field unless there has been radiographically and\u002For pathologically documented tumor progression in that lesion prior to enrollment.\n* No prior systemic therapy (see exclusion criteria, below)\n* Negative serum pregnancy test in women of childbearing potential\n* Patients with chronic HBV (HBsAg-positive with undetectable or low HBV DNA and normal ALT, or HBsAg-negative with anti-HBc-positive serology) and HCV (completed curative antiviral treatment with HCV viral load below the limit of quantification) may be eligible\n\n  * Patients with HBV should be treated with suppressive antiviral therapy prior to enrollment\n  * Patients with HCV must have completed curative therapy and have negative HCV viral load\n* Adequate organ function, as defined in Table 2:\n\nTable 2: Laboratory Parameters Required for Study Inclusion\n\nHematological Absolute neutrophil count (ANC): ≥ 1,500 \u002FmcL Platelets: ≥ 75,000 \u002F mcL Hemoglobin: ≥ 9g\u002FdL or ≥ 5.6 mmol\u002FL\n\nRenal Serum creatinine: ≤ 1.5 X upper limit of normal (ULN) OR Measured or calculated creatinine clearance: ≥ 60 mL\u002Fmin for patient with creatinine levels \\> 1.5 X institutional ULN (GFR can also be used in place of creatinine orCrCl)\n\nHepatic Serum total bilirubin: ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for patients with total bilirubin levels \\> 1.5 ULN except patients with Gilbert's disease (≤ 3x ULN) AST (SGOT) and ALT (SGPT): ≤ 2.5 X ULN OR ≤ 5 X ULN for patients with liver metastases\n\nExclusion Criteria:\n\n* Received any systemic therapy in the advanced or metastatic setting\n\n  * Adjuvant or neoadjuvant therapies received ≥ 1 year prior to enrollment are permitted\n* Unstable or deteriorating cardiovascular disease within the previous 6 months, including:\n\n  * Unstable angina or myocardial infarction\n  * CVA\u002Fstroke\n  * New York Heart Association \\[NYHA\\] Class III or IV congestive heart failure\n  * Uncontrolled clinically significant arrhythmias\n* Current use of immunosuppressive medication, EXCEPT for the following:\n\n  * Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection)\n  * Systemic corticosteroids at physiologic doses ≤ 10 mg\u002Fday of prednisone or equivalent\n  * Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n* Evidence of clinically significant immunosuppression such as the following:\n\n  * Primary immunodeficiency state such as Severe Combined Immunodeficiency Disease\n  * Concurrent opportunistic infection\n  * Receiving systemic immunosuppressive therapy (\\> 2 weeks) including oral steroid doses \\> 10 mg\u002Fday of prednisone or equivalent within 2 months prior to enrollment\n* History or evidence of symptomatic autoimmune disease in past 2 years prior to enrollment.\n\n  * Replacement therapy (e.g., thyroxine for hypothyroidism, insulin for diabetes or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment for autoimmune disease\n* Uncontrolled HIV infection, as defined by one or more of the following:\n\n  * Patients with CD4+ T-cell (CD4+) counts \\\u003C 350 cells\u002FuL\n  * Patients with a history of an opportunistic infection secondary to AIDS\n  * Patients on anti-microbials with drug-drug interactions with the study drugs on this protocol, who cannot be switched to alternative anti-microbials\n  * Patients on antiretroviral therapy \\\u003C 4 weeks\n  * Patients with HIV viral load \\> 400 copies\u002FmL\n* Active Hepatitis B or Hepatitis C\n* Patients who have received a live vaccine within 30 days of the start date of the planned study therapy (with the exception of COVID-19 vaccines)\n* History of active TB (Bacillus Tuberculosis)\n* Radiation therapy within 2 weeks prior to study day 1\n* If patient received major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting therapy\n* Women who are pregnant or breast feeding\n* Patients expecting to conceive or father children within the projected duration of the trial, starting with the visit through 180 days after the last dose of study treatment(s)\n* Prior organ transplantation including allogenic stem-cell transplantation\n* Active infection requiring systemic therapy\n* Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v5.0 Grade ≥ 3)\n* Patients with prior history of interstitial lung disease and clinically significant pulmonary compromise, including those who have a requirement for supplemental oxygen use to maintain adequate oxygenation",{"count":58,"type":21},98,[60,24],"PHASE1","This study is being done to find out whether the study drug Retifanlimab, a monoclonal antibody against the PD-1 protein, combined with gemcitabine and docetaxel, is a safe and effective treatment for your disease. Gemcitabine and docetaxel are chemotherapy drugs that are commonly used to treat soft tissue sarcoma. Retifanlimab is an experimental drug that boosts the immune system's ability to fight cancer cells. The study researchers think that Retifanlimab may help gemcitabine and docetaxel work better against soft tissue sarcoma that is either locally advanced or has spread beyond its original location (metastasized), and it cannot be removed with surgery (unresectable).",[63,64,32,27],"Soft Tissue Sarcoma","Sarcoma,Soft Tissue",[66,67,68,69,70,71,72,73],"soft tissue sarcoma","locally advanced soft tissue sarcoma","unresectable soft tissue sarcoma","metastasized soft tissue sarcoma","sarcoma","Retifanlimab","20-316","Memorial Sloan Kettering Cancer Center","2026-04-13",{"date":76,"type":41},"2026-04-14",{"date":78,"type":41},"2020-09-29",{"date":80,"type":21},"2026-09-29",{"name":73,"class":48},{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":102,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":49},"100626230","precision-medicine-approaches-for-neoadjuvant-therapy-in-high-risk-sarcoma-patients-100626230","NCT07432932","Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients","PANTHR-S","Inclusion Criteria:\n\n* Written informed consent for the prospective cohort\n\n  * Histopathological diagnosis of high-risk soft tissue sarcoma and one of the following subtypes: DDLPS, LMS, SS, vascular sarcomas or MPNST. Other subtypes may be included with PI approval.\n  * High-risk sarcoma definition:\n\n    * Greater than 5cm or Grade 3\n    * Deep anatomic location\n  * Have disease amenable to biopsy\n\n    o Patients who are not amenable to repeat biopsy at baseline can be reviewed with the local site PI for consideration of inclusion to the study\n  * Resectable tumour\n  * Measurable disease by RECIST 1.1\n  * Aged ≥ 18 years\n  * WHO performance status 0-2\n  * For patients receiving NCT, medically fit enough, with adequate organ function, to undergo neoadjuvant chemotherapy\n  * Patients medically fit enough to undergo surgical resection\n  * Capable of giving written informed consent (for prospective cohort) and comply with the study schedule\n  * Patients may also participate in the STRASS 2 trial\n\nExclusion Criteria:\n\n-Prior invasive malignancy in last 5 years, low risk malignancies in the last 5 years may be reviewed by the PI.\n\n* Known additional malignancy that is progressing or requires active treatment\n* Metastatic disease not amenable to curative intent local therapy\n* Any active uncontrolled medical conditions",{"count":90,"type":21},800,"OBSERVATIONAL","This is a cohort study aimed at developing a stratified medicine approach for personalised neoadjuvant chemotherapy (NCT) in high-risk soft tissue sarcoma (STS) patients with dedifferentiated liposarcoma (DDLPS), leiomyosarcoma (LMS), synovial sarcoma (SS), vascular sarcomas, malignant peripheral nerve sheath tumour (MPNST) or other subtypes. It comprises of both retrospective and prospective tissue collection from patients advancing directly to surgery (control group) and patients receiving NCT and surgery.",[32,94,95,96,27,29,30,97,98,99,100,101],"Sarcoma, Leiomyo-, Adult","Sarcoma, Synovial, Adult","Soft Tissue Sarcoma (STS)","Retroperitoneal Sarcoma","Liposarcoma, Dedifferentiated","Liposarcoma","Leiomyosarcoma (LMS)","Angiosarcoma",[103,104,105],"PANTHRS","PANTHRS-S","Sarcoma Accelerator","2026-02-18",{"date":108,"type":41},"2026-02-25",{"date":110,"type":41},"2021-11-19",{"date":112,"type":21},"2028-06-30",{"name":114,"class":48},"Royal Marsden NHS Foundation Trust",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":133,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100605961","phase-2-hypofractionated-3-week-preoperative-proton-or-x-ray-radiotherapy-for-patients-with-localized-soft-tissue-sarcoma-100605961","NCT07169344","Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma","PROSARC-1. Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma. A Single-arm, Multicenter, Phase II Clinical Trial.","PROSARC-1","Inclusion Criteria:\n\n1. ≥ 18 years of age at the time of informed consent.\n2. Histological diagnosis of STS, except rhabdomyosarcoma and Ewing sarcoma. Pleomorphic rhabdomyosarcomas are eligible.\n3. Primary tumor localized in head, neck, extremity, girdle and\u002For trunk wall.\n4. Measurable disease according to RECIST v1.1.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.\n6. Before patient registration, written informed consent must be given according to national and local regulations.\n7. Ability to fill in patient questionnaires and comply with study procedures, including travelling to Bergen or Oslo for PBT.\n\nExclusion Criteria:\n\n1. Locoregional or distant metastasis as assessed by CT and\u002For MRI at time of diagnosis. Patients with lung nodules \\\u003C10 mm of uncertain etiology may be included.\n2. Prior or concurrent malignant disease whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of this clinical trial are not eligible. Patients with a history of breast cancer, requiring continued hormonal treatment (e.g. anti-estrogen or an aromatase inhibitor) may be included. Patients with a history of prostate cancer, requiring continued support with luteinizing hormone releasing hormone (LHRH) agonists, with or without androgens, may be included.\n3. Previous radiotherapy to the primary tumor region.\n4. Patients with pacemakers and\u002For implanted defibrillators.\n5. Administration of systemic cancer therapy (i.e. chemotherapy, targeted therapy or immune therapy) within 14 days prior to the first fraction of radiotherapy.\n6. Patients not able to give an informed consent or comply with study regulations as deemed by study investigator.",{"count":124,"type":21},110,[24],"The purpose of the study is to investigate whether a personalized selection of patients with localized soft tissue sarcoma for preoperative proton radiation therapy can reduce long-term radiation side effects without increasing surgical complications or reducing the effectiveness of the treatment. Two radiation plans will be created for each patient-one for protons and one for photons-and through a national meeting, we will determine which type of radiation therapy each patient will receive. The radiation dose will be the same for both photons and protons.\n\nThe primary endpoint is surgical complications 120 days after surgery. Secondary endpoints include overall survival, local recurrence-free survival, disease-free survival, side effects, and quality of life. Furthermore, the study will investigate biomarkers that may predict response to radiation therapy, including changes in the tumor's genetic material (DNA), measurement of various molecules in the bloodstream, and the tumor's appearance on MRI scans.\n\nThe study will be conducted in Norway, with a planned inclusion of 110 patients.",[28,27,29,128,129,130,131,99,132],"Synovial Sarcomas","Leiomyosarcoma","Undifferentiated Pleomorphic Sarcoma (UPS)","Myxofibrosarcoma (MFS)","Pleomorphic Rhabdomyosarcoma",[134,135,136,137],"Soft tissue sarcoma","proton radiotherapy","x-ray radiotherapy","surgical complications","2026-01-26",{"date":140,"type":41},"2026-01-28",{"date":138,"type":41},{"date":143,"type":21},"2035-11-01",{"name":145,"class":48},"Oslo University Hospital",4,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":166,"leadSponsor":167,"locationsCount":168},"100606316","phase-2-dose-escalated-hypofractionated-definitive-proton-radiotherapy-for-patients-with-inoperable-soft-tissue-sarcoma-100606316","NCT07173972","Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.","PROSARC-2. Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. A Single-arm, Multicenter, Phase II Clinical Trial.","PROSARC-2","Inclusion Criteria:\n\n1. ≥ 18 years of age at the time of informed consent.\n2. Histological diagnosis of soft tissue sarcoma including gastrointestinal stromal tumor (GIST).\n3. Measurable disease according to RECIST v1.1.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\n5. For patients with metastatic disease a life-expectancy greater than 2 years should be expected.\n6. Before patient registration, written informed consent must be given according to national and local regulations.\n7. Ability to fill in patient questionnaires and comply with study procedures, including travelling to Bergen or Oslo for Proton Beam radiotherapy.\n\nExclusion Criteria:\n\n1. Patients with a prior or concurrent malignant disease whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of this clinical trial are not eligible. Patients with a history of breast cancer, requiring continued hormonal treatment (e.g. anti-estrogen or an aromatase inhibitor) may be included. Patients with a history of prostate cancer, requiring continued support with luteinizing hormone releasing hormone (LHRH) agonists, with or without androgens, may be included.\n2. Previous radiotherapy to the tumor site.\n3. Patients with pacemakers and\u002For implanted defibrillators.\n4. Patients not able to give an informed consent or comply with study regulations as deemed by study investigator.\n5. Administration of systemic cancer therapy (i.e. chemotherapy, targeted therapy or immune therapy) within 14 days prior to the first fraction of radiotherapy.",{"count":156,"type":21},40,[24],"The purpose of the study is to study if dose escalated proton radiotherapy can improve local controll for patients with inoperable soft tissue sarcomas. The standard treatment is photon-based radiation. By using proton radiotherapy instead, the hypothesis is that the dose can be increased to enhance treatment effectiveness without increasing side effects.\n\nThe planned radiation dose is 56 Gy in 16 fractions (treatments) over 4 weeks (4 fractions per week), with a maximum dose escalation centrally in the tumor up to 80 Gy (5 Gy per fraction).\n\nAt the same time, the study will investigate biomarkers that can predict treatment response, including changes in the tumor's genetic material (DNA), measurements of various molecules in the bloodstream, and the tumor's appearance on MRI scans.\n\nThe primary endpoint is local control after 2 years, meaning that the treated tumor has not grown during this period. Secondary endpoints include overall survival, progression-free survival, radiological response rates, side effects, and quality of life.\n\nThe study will be conducted in Norway, with a planned inclusion of 40 patients.",[96,27,29,128,130,160,100,161,132,99],"Myxofibrosarcoma","Pleomorphic Liposarcoma",[66,135,163],"inoperable soft tissue sarcoma",{"date":140,"type":41},{"date":138,"type":41},{"date":143,"type":21},{"name":145,"class":48},2,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":185,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":5},"100453255","phase-2-combination-of-pembrolizumab-and-cabozantinib-in-patients-with-advanced-sarcomas-100453255","NCT05182164","Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas","PEMBROCABOSARC","Inclusion Criteria:\n\n1. Histology: undifferentiated pleomorphic sarcoma (stratum 1), bone osteosarcoma (stratum 2), bone or extraskeletal or Ewing sarcoma (stratum 3),\n2. Advanced non resectable \u002F metastatic disease,\n3. Recurrent disease or progression after standard therapy,\n4. Documented progression according to RECIST criteria.\n5. Have provided tissue of a tumor lesion from \\\u003C 3 months old archival tissue sample obtained on locally advanced disease, or metastatis with no subsequent treatment since or from a newly obtained core or excisional biopsy,\n6. No more of three previous lines of systemic therapy for advanced disease,\n7. Age ≥ 18 years,\n8. Eastern Cooperative Oncology Group ≤ 1,\n9. Measurable disease according to RECIST v1.1 outside any previously irradiated field. At least one site of disease must be uni-dimensionally ≥ 10 mm,\n10. Life expectancy \\> 3 months,\n11. Participant must have advanced disease and must not be a candidate for other approved therapeutic regimen known to provide significant clinical benefit based on investigator judgement,\n12. No symptomatic central nervous system disease,\n13. No chronic use of glucocorticoids.\n14. Adequate hematological, renal, metabolic and hepatic function,\n15. No prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma,\n16. At least three weeks since last chemotherapy, immunotherapy and two weeks for any other pharmacological treatment and\u002For radiotherapy,\n17. Recovery to grade ≤ 1 from any adverse event (AE) derived from previous treatment (excluding alopecia of any grade, non-painful peripheral neuropathy grade ≤ 2 and endocrine-related grade ≤ 2 requiring treatment or hormone replacement) (according to NCI-CTCAE, version 5.0). For patients previously treated by radiotherapy, they must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis,\n18. Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication. Both women and men must agree to use 2 medically acceptable methods of contraception throughout the treatment period and for 6 months after discontinuation of treatment. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for ≥ 1 year,\n19. Voluntary signed and dated written informed consents prior to any specific study procedure,\n20. Patients with a social security in compliance with the French Law.\n\nExclusion Criteria:\n\n1. Previous treatment with Pembrolizumab or Cabozantinib,\n2. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumabor any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways),\n3. Evidence of progressive or symptomatic central nervous system or leptomeningeal metastases,\n4. Men or women of childbearing potential who are not using an effective method of contraception; women who are pregnant or breast feeding, men or women who are planning to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment,\n5. Participation to a study involving a medical or therapeutic intervention in the last 21 days,\n6. Previous enrolment in the present study,\n7. Patient unable to follow and comply with the study procedures because of any geographical, familial, social or psychological reasons,\n8. Patient unable to swallow,\n9. Known hypersensitivity to any involved study drug or of its formulation components,\n10. Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy is not considered a form of systemic treatment and is allowed.\n11. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment,\n12. History of idiopathic pulmonary fibrosis, history of non-infectious pneumonitis that required steroids, current pneumonitis\u002Finterstitial lung disease, drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted,\n13. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection.\n14. Has a known history of HIV infection and\u002For of active TB (Bacillus Tuberculosis),\n15. Treatment with anticoagulants such as anti-Vitamin K, thrombin or Factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel),\n16. Previous allogenic bone marrow transplant or solid organ transplantation,\n17. Has an active infection requiring systemic treatment at study entry,\n18. The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) \\> 500 ms within 28 days before treatment. Note: if initial QTcF is found to be \\> 500 ms, two additional ECGs separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is ≤ 500 ms, the subject meets eligibility in this regard,\n19. The subject requires chronic concomitant treatment of strong CYP3A4 inducers\n20. The subject has experienced any of the following: Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment, Hemoptysis of ≥ 2.5 mL of red blood within 3 months before the first dose of study treatment, Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment, The subject has radiographic evidence of cavitating pulmonary lesion(s), The subject has tumor in contact with, invading or encasing any major blood vessels, or The subject has evidence of tumor invading the GI tract, or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib.\n21. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions which are fully described in the study protocol: Cardiovascular disorders, Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation, Other disorders associated with a high risk of fistula formation including PEG tube placement within 3 months before the first dose of study therapy,\n22. Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Note: Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.\n23. Has an history or current evidence of any condition, therapy, or laboratory abnormality that might counfound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n24. The subject is planning to have oral surgery\u002Finvasive dental procedure within the projected duration of the study, starting with the screening visit through 3 months after the last dose of study treatment or had such a procedure within 3 months of first dose of study treatment.",{"count":177,"type":21},119,[24],"Phase II trial with three independent strata to independently assess the effects of the association of pembrolizumab and cabozantinib in advanced sarcomas.",[27,181,182,183,184],"Advanced Soft-tissue Sarcoma","Ewing Sarcoma","Osteosarcoma","Undifferentiated Pleomorphic Sarcoma",[186,187],"soft-tissue sarcoma","immune checkpoint inhibitor","2025-10-01",{"date":190,"type":41},"2025-10-07",{"date":192,"type":41},"2022-04-25",{"date":194,"type":21},"2027-12",{"name":196,"class":48},"Institut Bergonié",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":207,"conditions":208,"keywords":211,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":49},"100569886","early-phase-1-a-phase-0-multicenter-study-of-the-pharmacodynamic-effects-of-intratumoral-microdose-administration-of-pba-0111-in-patients-with-solid-tumors-100569886","NCT06700070","A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors","Inclusion Criteria:\n\n1\\. Ability and willingness to comply with the study's visit and assessment schedule. 2. Male or female ≥ 18 years of age at Visit 1 (Screening). 3. Pathologic diagnosis of HNSCC, STS (see restrictions in Note below), or TNBC (see restrictions in Note below; TNBC defined as estrogen receptor negative \\[\\\u003C1% positive tumor cells\\], progesterone receptor negative \\[\\\u003C1% positive tumor cells\\], and human epidermal growth factor receptor 2 negative \\[0 to 1+\\]) with a tumor planned for surgical resection. Note: For STS, only the following subtypes are eligible: undifferentiated pleomorphic sarcoma, alveolar soft part sarcoma, synovial sarcoma, cutaneous angiosarcoma, or myxofibrosarcoma. Note: For TNBC, if prior neoadjuvant therapy, evidence of progressive disease, at the discretion of the investigator. 4. Ability and willingness to provide written informed consent. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care. 5. As assessed or confirmed by the surgeon, at least one lesion (primary tumor, recurrent tumor, metastatic tumor, or metastatic lymph node) that is surface accessible for CIVO injection that contains viable minimum tumor tissue volume and characteristics (e.g., based on clinical evaluation, available pre-operative imaging, pre-injection ultrasound imaging, or pathology reports indicating lesion with appropriate viable tumor volume without excessive cysts or necrosis) and for which there is a planned surgical intervention. The patient's presentation, surgical and pathology plan may determine whether a lesion is eligible with respect to a given CIVO MID needle configuration. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 7. Female patients who: • Are postmenopausal for at least one year before the screening visit, OR • Are surgically sterile, OR • Are of childbearing potential who agree to practice a highly effective method of contraception from the time of signing the ICF up to 3 months following the end of study participation OR agree to completely abstain from heterosexual intercourse. • Agree to refrain from donating ova during study participation. Male patients, even if surgically sterile (i.e., status post-vasectomy), who: • Agree to practice effective barrier contraception from the time of signing the ICF up to 3 months following the end of study participation OR agree to completely abstain from heterosexual intercourse. • Agree to refrain from donating sperm during study participation.\n\nExclusion Criteria:\n\n1\\. Tumors near or involving critical structures for which, in the opinion of the treating clinician, injection would pose undue risk to the patient. 2. Female patients who are: • Both lactating and breastfeeding, OR • Have a positive β-subunit human chorionic gonadotropin (β-hCG) pregnancy test at screening verified by the Investigator. 3. Any uncontrolled intercurrent illness, condition, serious medical or psychiatric illness, or circumstance that, in the opinion of the Investigator, could interfere with adherence to the study's procedures or requirements, or otherwise compromise the study's objectives. 4. HNSCC known to be of cutaneous origin. 5. Patients with uncontrolled autoimmune diseases (see Appendix 1 for examples) requiring systemic treatment 6. Patients with known HIV\u002FAIDS. 7. Patients with known uncontrolled active hepatitis B (defined as hepatitis B surface antigen \\[HBsAg\\] positive or detectable hepatitis B virus \\[HBV\\] DNA) or hepatitis C (defined as anti-hepatitis C virus antibody \\[anti-HCV Ab\\] positive and detectable hepatitis C virus \\[HCV\\] RNA) infection. Note: Hepatitis B and C screening tests are not required unless: • Patient has a known history of hepatitis B\u002FC infection • Mandated by local health authority 8. Use of any of the following ≤ 3 weeks prior to CIVO injection: a. Systemic anti-cancer therapy (e.g., cytotoxic chemotherapy, targeted agents, or checkpoint inhibitor immunotherapy, etc.), b. Immunosuppressive drugs (e.g., calcineurin inhibitors) c. Biological response modifiers for autoimmune disease d. Systemic glucocorticoids: oral or parenteral corticosteroids at a dose ≥ 20 mg\u002Fday prednisone, or equivalent Note: physiologic replacement dosing of steroids (≤ 3 mg\u002Fm2\u002Fd prednisone or equivalent), low-dose corticosteroids for dye allergies prior to staging scans or use in anti-emetic prophylaxis for patients undergoing chemotherapy, or topical steroids, are allowed e. Hematopoietic growth factors f. Chemotherapy g. Local radiotherapy of the target lesion planned for CIVO injection and surgical resection 9. Patients who have received a live or live attenuated vaccine within 4 weeks of the baseline\u002Fscreening visit. 10. Patients who have had allogenic tissue\u002Fsolid organ transplant 11. Patients with an active infection requiring systemic therapy. 12. Patients for whom participation on this study results in a delay of planned surgical intervention.",{"count":204,"type":21},12,[206],"EARLY_PHASE1","This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in microdose quantities via the CIVO device.",[209,27,210],"Head and Neck Squamous Cell Carcinoma","Triple Negative Breast Cancer",[212,213,214,215,216,217,218,219,220,221,222,223],"Pure Biologics","PBA-0111","TNBC","STS","HNSCC","tumor microenvironment","in vivo drug sensitivity","in vivo oncology","microdosing","microinjection","intratumoral injection","precision oncology","2025-08-05",{"date":226,"type":41},"2025-08-11",{"date":228,"type":41},"2025-03-27",{"date":230,"type":21},"2025-12",{"name":232,"class":233},"Pure Biologics S.A.","INDUSTRY",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":22,"phases":242,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":49},"100545698","blood-and-tissue-extraction-for-immunological-examinations-during-neoadjuvant-therapy-of-soft-tissue-sarcomas-100545698","NCT06385288","Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas","Inclusion Criteria:\n\n* Planned histological confirmation for especially high-risk soft tissue sarcoma via open Sampling\n* Indication for neoadjuvant multimodal therapy (radiation and locoregional Hyperthermia, optionally with simultaneous chemotherapy)\n* Planned resection of a department of the CWS\n* Age \\> 18 years\n* Ability to consent\n* Additionally for imaging study: Treatment on the combined MR hyperthermia device\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Poor understanding (language etc.)\n* Lack of reconnaissance ability",{"count":241,"type":21},30,[243],"NA","\"Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcoma\" is a prospective study with additional translational research using preoperative and postoperative tissue, blood sampling and advanced imaging.",[27],[247,248,249,250],"Soft tissue sarcomas","immunological examinations","neoadjuvant therapy","radiotherapy","2024-12-03",{"date":253,"type":41},"2024-12-06",{"date":255,"type":41},"2021-07-21",{"date":257,"type":21},"2031-07-21",{"name":259,"class":48},"University Hospital Tuebingen",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":273,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":146},"100513153","phase-2-propranolol-and-pembrolizumab-in-advanced-soft-tissue-sarcoma-patients-100513153","NCT05961761","Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients","An Open Label Phase 2 Study on Propranolol and Pembrolizumab in Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma - a Scandinavian Sarcoma Group Collaboration","PROPANE","Inclusion Criteria:\n\n* Subjects must have signed and dated an IRB\u002FIEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care\n* Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study\n* Histologically confirmed diagnosis of unresectable locally advanced or metastatic Angiosarcoma or Undifferentiated Pleomorphic Sarcoma, who has progressed\u002Ffailed to provide clinical benefit on first line standard chemotherapy.\n* Age ≥18 years\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of ≤2 at the time of enrollment.\n* Evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).\n* Available material from archived formalin-fixed paraffin-embedded tumor tissue obtained within 3 months of study enrollment for biomarker related studies. If not sufficient or available, a newly obtained core or excisional biopsy of a tumor lesion may be performed.\n* Patients must have normal organ and marrow function as defined below:\n* Absolute neutrophil count (ANC) ≥ 1 x 10⁹\u002FL\n* Platelet count ≥ 75 x 10⁹\u002FL\n* Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) (patients with Gilbert's Syndrome must have a total bilirubin ≤ 50 mmol\u002FL)\n* Aspartate transaminase (AST)\u002FAlanine transaminase (ALT) ≤ 5 x ULN\n* Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL\u002Fmin (using the Cockcroft-Gault formula)\n* Women of childbearing potential (WOCBP): Agreement to use contraceptive methods with a failure rate of \\\u003C 1 % per year during the treatment period and for at least 120 days after the treatment. Safe contraceptive methods for women are birth control pills, intrauterine device, contraceptive injection, contraceptive implant,contraceptive patch or contraceptive vaginal ring.\n* Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year during the treatment period and for at least 120 days after the treatment.\n* Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception\n\nExclusion Criteria:\n\n* Have an anticipated life expectancy of \\\u003C3 months.\n* Moderate to severe degree of bronchial asthma or chronic obstructive pulmonary disease.\n* Acute or non-stable congestive heart failure\n* Any other condition listed as contraindication for treatment with propranolol according to SPC\n* Have received any previous systemic therapy targeting the PD-1\u002FPDL-1 signaling pathway or other immune checkpoint inhibitors.\n* Have received propranolol within 4 weeks prior to treatment.\n* Prior to study day one received radiation therapy, chemotherapy or targeted small molecule therapy within 2 weeks and\u002For monoclonal antibody treatment within 4 weeks.\n* Not recovered from the effects of previously administered agents\n* Clinically active or unstable CNS metastases as assessed by the treating physician\n* Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results\n* Participants with active, known or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism Inclusion criteria\n* Subjects must have signed and dated an IRB\u002FIEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care\n* Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study\n* Histologically confirmed diagnosis of unresectable locally advanced or metastatic Angiosarcoma or Undifferentiated Pleomorphic Sarcoma, who has progressed\u002Ffailed to provide clinical benefit on first line standard chemotherapy.\n* Age ≥18 years\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of ≤2 at the time of enrollment.\n* Evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).\n* Available material from archived formalin-fixed paraffin-embedded tumor tissue obtained within 3 months of study enrollment for biomarker related studies. If not sufficient or available, a newly obtained core or excisional biopsy of a tumor lesion may be performed.\n* Patients must have normal organ and marrow function as defined below:\n* Absolute neutrophil count (ANC) ≥ 1 x 10⁹\u002FL\n* Platelet count ≥ 75 x 10⁹\u002FL\n* Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) (patients with Gilbert's Syndrome must have a total bilirubin ≤ 50 mmol\u002FL)\n* Aspartate transaminase (AST)\u002FAlanine transaminase (ALT) ≤ 5 x ULN\n* Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL\u002Fmin (using the Cockcroft-Gault formula)\n* Women of childbearing potential (WOCBP): Agreement to use contraceptive methods with a failure rate of \\\u003C 1 % per year during the treatment period and for at least 120 days after the treatment. Safe contraceptive methods for women are birth control pills, intrauterine device, contraceptive injection, contraceptive implant,contraceptive patch or contraceptive vaginal ring.\n* Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year during the treatment period and for at least 120 days after the treatment.\n* Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception\n\nExclusion criteria\n\n* Have an anticipated life expectancy of \\\u003C3 months.\n* Moderate to severe degree of bronchial asthma or chronic obstructive pulmonary disease.\n* Acute or non-stable congestive heart failure\n* Any other condition listed as contraindication for treatment with propranolol according to SPC\n* Have received any previous systemic therapy targeting the PD-1\u002FPDL-1 signaling pathway or other immune checkpoint inhibitors.\n* Have received propranolol within 4 weeks prior to treatment.\n* Prior to study day one received radiation therapy, chemotherapy or targeted small molecule therapy within 2 weeks and\u002For monoclonal antibody treatment within 4 weeks.\n* Not recovered from the effects of previously administered agents\n* Clinically active or unstable CNS metastases as assessed by the treating physician\n* Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results\n* Participants with active, known or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.\n* Participants with a condition requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone equivalents) or other immunosuppressive medications. Inhaled or topical steroids and adrenal replacement doses \\> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.\n* Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)\n* Allergies and Adverse Drug Reaction\n* History of allergy to study drug components\n* History of severe hypersensitivity reaction to any monoclonal antibody\n* WOCBP who are pregnant or breastfeeding",{"count":269,"type":21},80,[24],"The goal of this phase 2 clinical trial is to test efficacy and tolerability of combining propranolol and pembrolizumab in patients with advanced angiosarcoma or undifferentiated pleomorphic sarcoma. The main questions aims to answer:\n\n* Primary: determine the progression-free survival rate (PFSR) at 3 months\n\nSecondary: determine the objective response rate (ORR), duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS). Ensure the safety and tolerability, Determine Quality of Life (QoL)\n\n• Exploratory: Characterize the TME\n\nParticipants will be asked to ensure\n\n* Baseline biopsy and further optional biopsies\n* Treatment propranolol 40 mg BID and pembrolizumab 2 mg\u002Fkg Q3 weeks\n* Evaluation, blood counts, QoL and blood samples for biomarkers according to schedule",[27,101,184],[274,275,276,277,32],"Immunotherapy","Propranolol","Pembrolizumab","PD-1 inhibitor","2023-07-23",{"date":280,"type":41},"2023-07-27",{"date":282,"type":41},"2021-08-17",{"date":284,"type":21},"2028-12",{"name":286,"class":48},"Niels Junker",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":49},"100387877","combined-treatment-of-patients-with-soft-tissue-sarcoma-including-preoperative-stereotactic-radiation-therapy-and-postoperative-conformal-radiation-therapy-100387877","NCT04330456","Combined Treatment of Patients With Soft Tissue Sarcoma Including Preoperative Stereotactic Radiation Therapy and Postoperative Conformal Radiation Therapy","Inclusion Criteria:\n\n* morphologically verified diagnosis of soft tissue sarcoma\n* first diagnosed tumor process\n* ability to perform radical surgery\n* signed informed consent\n* indications for stereotactic and conformal radiation therapy\n* no contraindications for radiation and surgical treatment\n\nExclusion Criteria:\n\n* previous radiation treatment\n* acute infection\n* pregnancy, lactation\n* recurrent tumor\n* refuse to sign informed consent\n* conditions that can affect the outcome of treatment (immunodeficiency, tuberculosis, etc.)\n* tumor topography and volume that don't allow to perform stereotactic and conformal radiation therapy.","75 Years",{"count":241,"type":21},[243],"Combined treatment of soft tissue sarcoma includes 3 steps:\n\n1. step - preoperative stereotactic radiation therapy in hypofractionation mode\n2. step - operation\n3. step - postoperative conformal radiation therapy in normofractionation mode",[27],"2020-03-31",{"date":300,"type":41},"2020-04-01",{"date":302,"type":41},"2020-02-01",{"date":304,"type":21},"2028-07-01",{"name":306,"class":48},"N.N. Petrov National Medical Research Center of Oncology","Soft Tissue Sarcoma, Adult"]